Diazepam Patent Expiration
Diazepam was first introduced by Waylis Therapeutics Llc
Diazepam Patents
Given below is the list of patents protecting Diazepam, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Libervant | US11273131 | Pharmaceutical compositions with enhanced permeation | Jun 18, 2038 | Aquestive |
| Valtoco | US12324852 | Administration of benzodiazepine compositions | Oct 16, 2032 | Neurelis Inc |
| Valtoco | US12337061 | Administration of benzodiazepine compositions | Jun 13, 2032 | Neurelis Inc |
| Valtoco | US11241414 | Administration of benzodiazepine compositions | Mar 27, 2029 | Neurelis Inc |
| Valtoco | US11793786 | Administration of benzodiazepine compositions | Mar 27, 2029 | Neurelis Inc |
| Valtoco | US12268664 | Administration of benzodiazepine compositions | Mar 27, 2029 | Neurelis Inc |
| Valtoco | US8895546 | Administration of benzodiazepine compositions | Mar 27, 2029 | Neurelis Inc |
| Valtoco | US9763876 | Administration of benzodiazepine compositions | Mar 27, 2029 | Neurelis Inc |
| Valtoco | US8927497 | Absorption enhancers for intranasal administration |
Jul 21, 2025
(Expired) | Neurelis Inc |
| Valtoco | US10265402 | Absorption enhancers for drug administration |
May 11, 2025
(Expired) | Neurelis Inc |
| Valtoco | US9642913 | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent |
May 11, 2025
(Expired) | Neurelis Inc |
| Diastat | US5462740 | Rectally-administered, epileptic-seizure-inhibiting composition |
Sep 17, 2013
(Expired) | Bausch |
| Diastat Acudial | US5462740 | Rectally-administered, epileptic-seizure-inhibiting composition |
Sep 17, 2013
(Expired) | Bausch |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Diazepam's patents.
Latest Legal Activities on Diazepam's Patents
Given below is the list recent legal activities going on the following patents of Diazepam.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent eGrant | 24 Oct, 2023 | US11793786 |
| Patent eGrant Notification | 24 Oct, 2023 | US11793786 |
| Patent Issue Date Used in PTA Calculation Critical
| 24 Oct, 2023 | US11793786 |
| Recordation of Patent Grant Mailed Critical
| 24 Oct, 2023 | US11793786 |
| Mail Patent eGrant Notification | 24 Oct, 2023 | US11793786 |
| Email Notification Critical
| 24 Oct, 2023 | US11793786 |
| Email Notification Critical
| 05 Oct, 2023 | US11793786 |
| Issue Notification Mailed Critical
| 04 Oct, 2023 | US11793786 |
| Dispatch to FDC | 19 Sep, 2023 | US11793786 |
| Application Is Considered Ready for Issue Critical
| 19 Sep, 2023 | US11793786 |
Diazepam's Family Patents
